BioNTech Names Guido Oelkers CEO as Oncology Pivot Accelerates

References

1. 1.Joseph, A. (2026, August 3). BioNTech names Guido Oelkers its new CEO. STAT News. https://www.statnews.com/2026/08/03/biontech-ceo-guido-oelkers-ugur-sahin-replacement/
2. 2.Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261–279. https://doi.org/10.1038/nrd.2017.243
3. 3.Sahin, U., & Türeci, Ö. (2018). Personalized vaccines for cancer immunotherapy. Science, 359(6382), 1355–1360. https://doi.org/10.1126/science.aar7112
4. 4.Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., Yu, R., Chandra, A. K., Waters, T., Ruan, J., Amisaki, M., Zebboudj, A., Odgerel, Z., Payne, G., Derhovanessian, E., … Balachandran, V. P. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature, 618, 144–150. https://doi.org/10.1038/s41586-023-06063-y
5. 5.Türeci, Ö., Vormehr, M., Diken, M., Kreiter, S., Huber, C., & Sahin, U. (2016). Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clinical Cancer Research, 22(8), 1885–1896. https://doi.org/10.1158/1078-0432.CCR-15-2509
6. 6.Hartmann, J. T., Haap, M., Kopp, H. G., & Lipp, H. P. (2009). Tyrosine kinase inhibitors — a review on pharmacology, metabolism and side effects. Current Drug Metabolism, 10(5), 470–481. https://doi.org/10.2174/138920009789895126
7. 7.Moderna, Inc. (2024). Moderna and Merck announce mRNA-4157/V940 Phase 3 KEYNOTE-942 trial results in melanoma [Press release]. https://investors.modernatx.com/news-releases/news-release-details/moderna-and-merck-announce-mrna-4157v940-phase-3-keynote-942
8. 8.Australian Government Department of Health and Aged Care. (2023). Horizon scanning for health technologies: Framework and methodology. Medical Services Advisory Committee (MSAC). https://www.msac.gov.au/internet/msac/publishing.nsf/Content/horizon-scanning